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Type 2 diabetes (T2D) affects 415 million people worldwide, and has a much higher 
prevalence in Hispanics (16.9%), compared to non-Hispanic whites (10.2%). Genome-
wide association studies and whole-genome and whole-exome sequencing studies 
have discovered more than 100 genetic regions associated with modified risk for T2D. 
However, the identified genetic factors explain a very small fraction of the estimated 
heritability. Until recently, little attention has been put in studying other non European 
populations that suffer from a higher burden of T2D, such as Hispanics/Latinos. In the 
past few years, genetic studies in Hispanic populations have started to provide new 
insights into the genetic architecture of T2D in this ancestry group. Of note, several 
genetic variants that are absent or very rare in non-Hispanic populations but more 
common in Hispanics have shown from moderate to strong association with T2D and 
have provided new insights into the biology of T2D, which may be ultimately useful 
for developing novel therapeutic strategies applicable to all populations. Studying 
diverse populations can also improve the ability to find the causal variants in known 
T2D loci by a multi-ancestry fine-mapping approach, which leverages the different 
patterns of linkage disequilibrium between the causal and the ascertained genetic 
variants. In this mini-review, we summarize the main genetic findings discovered in 
Hispanics and discuss the limitations and challenges of performing genetic studies in 
these populations. Finally, we present possible next steps to make studies in Latino 
populations more valuable in providing a deeper understanding of T2D and anticipate 
their future application to the development of predictive and preventive medicine and 
personalized therapies.
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inTRODUCTiOn
Type 2 diabetes (T2D) affects more than 415 million people worldwide and is predicted to be the 7th 
leading cause of death in 2030 (1). T2D is particularly prevalent in Latin Americans (14.4%, twice as 
high as for non-Hispanic whites in the US), where it is one of the leading causes of death (2, 3). While 
different environmental and lifestyle risk factors in Latin America partially explain the increased 
prevalence of T2D, unique genetic influences also contribute (4, 5).
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Genome-wide association studies (GWAS) have been able 
to identify more than 100 loci associated with T2D. However, 
until very recently, most GWAS have been performed in 
populations of European ancestry (6). Even in the largest trans-
ancestry GWAS meta-analysis published to date, less than 40% 
of the samples are of non-European ancestry, and only 2% of 
Hispanic ancestry (7).
Genetic studies in diverse populations are essential for several 
reasons. First, finding a population-specific variant associated 
with T2D can help identify subjects at high risk for T2D in that 
particular population, who could be selected for lifestyle or 
therapeutic preventive intervention. Second, the discovery of 
causal genes in these populations can expand our understand-
ing of T2D or lead to a potential therapeutic target that could 
be valuable even in populations where the genetic variant that 
prompted the discovery is not present.
During the past few years, several studies conducted in Latino 
populations have revealed novel associations that have improved 
our knowledge of the biology of T2D, and also proposed novel 
therapeutic targets or personalized strategies. In this review, we 
will describe such studies and illustrate how they might lead to 
potential therapeutic targets for T2D. Finally, we will suggest 
future research to improve the performance and interpretation 
of GWAS in non-European populations.
OveRview OF GeneTiC STUDieS 
PeRFORMeD in LATinO POPULATiOnS
The first GWAS for T2D in Hispanic populations was performed 
in the Mexican American population of Starr County in 2011 (8, 
9). Although no novel loci were identified at genome-wide statis-
tical significance (P < 5 × 10−8, selected empirically to correct for 
the number of independent tests among common variants in the 
human genome), the authors replicated several loci previously 
found in European populations, indicating that the majority of 
common genetic risk factors are transferrable to Latin American 
populations.
Studies from the Slim initiative for 
Genomic Medicine (SiGMA) T2D 
Consortium
As part of the SIGMA, the SIGMA T2D Consortium has shed 
new light on the genetic architecture of T2D in Mexicans, and 
resulted in several discoveries that may result in future therapeu-
tic strategies (summarized below and in Figure 1 and Table 1).
SLC16A11
In 2014, by analyzing 8,214 individuals from Mexico together 
with Latinos living in southern California, the first locus 
specific to Mexicans and Latin Americans was identified (4). 
This novel locus spanned the solute carrier family 16 mem-
ber 11 (SLC16A11) and solute carrier family 16 member 11 
(SLC16A13) genes and represented one of the strongest signals 
identified to date [odds ratio (OR) = 1.29, 95% CI 1.20–1.38, 
P =  5.4 ×  10−12], in a haplotype present at ~30% frequency 
in Mexico, ~10% in East Asian, and rare in Europeans and 
African Americans. Simultaneously, a genome-wide signifi-
cant signal was identified in East Asians near SLC16A13, in a 
variant which is in tight linkage disequilibrium with the top 
variant identified in Mexicans (r2 = 0.97), and, therefore, likely 
representing and replicating the same signal (10). Recent 
studies also suggest that this same locus is also associated with 
childhood T2D in Mexicans (11), it interacts with body-mass 
index in Native Americans, showing a stronger association in 
lean individuals (12).
Further fine-mapping and functional studies revealed that 
variants in this haplotype reduce the function of SLC16A11 
by two independent mechanisms, both decreasing its expres-
sion in the liver and disrupting its interaction with basigin, 
a chaperone that mediates the transport of SLC16A11 to the 
plasma membrane. The authors also investigated the role of the 
SLC16A11 protein, and categorized this previously uncharac-
terized transporter as a proton-coupled monocarboxylate 
transporter. Disruption of expression of SLC16A11 induces 
changes in fatty acid and lipid metabolism that are associ-
ated with T2D (13). These findings suggest that increasing 
SLC16A11 function in the appropriate target tissue could be 
beneficial to prevent or treat T2D. Future work will be needed 
to identify the specific variants that mediate these effects and 
to understand how the reduction of SLC16A11 activity results 
in increased risk of T2D.
HNF1 Homeobox A Gene
The analysis of whole-exome sequences in ~3,700 individuals 
in the same Latino population resulted in the identification of 
a novel non-synonymous and population-specific variant in the 
hepatic nuclear factor 1 (HNF1) homeobox A gene (HNF1A) 
that was strongly associated with T2D (rs483353044, encod-
ing p.E508K, OR = 4.96, 95% CI 2.83–10.61; P = 4.4 × 10−7), 
conferring one of the highest effect sizes identified at that time 
(5). This variant was present in 0.36% of individuals without 
T2D but in 2.1% of participants with the disease; because of its 
low frequency in a single ethnic group, it could have only been 
identified through sequencing approaches. This variant causes 
an amino acid change from glutamate to lysine in the HNF1A 
gene, one of the genes which when mutated causes maturity 
onset diabetes of the young (MODY). Functional exploration 
of transcriptional activity suggests that this variant confers 
an intermediate molecular phenotype between MODY and 
common T2D, although carriers of this variant are clinically 
indistinguishable from non-carriers with T2D, highlighting 
the need to use genetic methods to identify them. Patients 
with MODY who carry complete loss-of-function mutations in 
HNF1A have improved sensitivity to sulfonylureas, compared to 
insulin and metformin treatment (14, 15). This suggests that the 
2% of individuals who carry this variant in Mexico might benefit 
from sulfonylurea therapy over metformin once identified by 
genotyping, potentially avoiding the consequences of several 
cycles of trial-and-error medication testing. However, pharma-
cogenetic studies that test this hypothesis are needed, though 
they need to be conducted at sites where carriers of this variant 
reside, necessitating the deployment of new infrastructures for 
“recalling by genotype.”
FiGURe 1 | Overview of genetic associations with the potential to develop into new therapeutic strategies within SLC16A11 (A,B) and IGF2 (C–e). (A) Fine mapping 
of the SLC16A11 region identified in Williams et al. (4) mapped and revealed several candidate variants at or near SLC16A11 gene. Each dot represents a variant 
within the 99% credible set, i.e,. the variants that have, in aggregate 99% probability of containing the causal variant. The y-axis represents the posterior probability 
of being causal, and the x-axis the genomic position (Hg19). The lead SNP is represented by the purple symbol. The color-coding scheme indicates the R-squared 
with the lead SNP, estimated based on the Mexican population. Only the SNPs that fall within the 99% credible set are plotted. (B) The type 2 diabetes (T2D) risk 
haplotype contains a cis-eQTL associated with lower SLC16A11 expression in the liver. In addition, coding risk alleles in the same haplotype disrupt the interaction 
between SLC16A11 and basigin (BSG). Reduced SLC16A11 expression was shown to induce metabolic changes associated with T2D. (C) rs149483638 prevents 
splicing in vitro and in vivo. This variant is located at a canonical splice acceptor site, and is predicted to cause skipping of exon 2 of IGF2 isoform 2. (D) The dosage 
of the T2D protective A allele is correlated with lower expression of IGF2 isoform 2 (as measured by expression levels of the exon 1–2 junction) in liver and in adipose 
tissue. (e) Expression of IGF2 isoform 2 is associated with T2D and glycated hemoglobin (HbA1c). Boxplots representing the expression of IGF2 isoform 2 across 
T2D cases and controls in individuals homozygous for the G common allele. The linear model P-value represents the association between IGF2 isoform 2 
expression, adjusted by age, body mass index, and sex. The IGF2 isoform 2 positively correlates with higher plasma HbA1c in participants without diabetes. Figure 
adapted from Rusu et al. (13), Copyright 2017 by Elsevier with permission and Mercader et al. (17) American Diabetes Association and Copyright Clearance Center 
with permission.
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Insulin-Like Growth Factor 2
SIGMA T2D participants were also genotyped with the exome 
chip, which is a cost-effective genotyping array designed to 
capture low-frequency coding variants. This analysis identified 
a loss-of-function variant that was associated with 20% reduced 
risk of T2D (rs149483638, OR  =  0.78, 95% CI 0.73–0.84, 
P = 5.6 × 10−14) (16). This variant was present at a frequency 
of ~17% in the Mexican population but was rare in Europe and 
other populations. The T2D protective allele disrupts a canoni-
cal acceptor splice-site that results in reduced levels of a minor 
isoform of insulin-like growth factor 2 (IGF2), isoform 2. We 
demonstrated that this variant prevents the expression of this 
isoform in vitro, and that carriers of this variant show reduced 
expression of isoform 2 IGF2 in liver and adipose tissue ex 
TABLe 1 | Novel genome-wide significant associations identified in Latino populations.
Target gene Lead variant Odds ratio (95% Ci) 
(Latino/eA)
P-value  
(Latino/eA)
MAF 
(Latino)
MAF  
(eU)
MAF (eA) MAF  
(SA)
MAF  
(AA)
Reference
SLC16A11 rs77086571 1.29 (1.20–1.38)/ 
1.20 (1.14–1.26)a
5.4 × 10−12/7.9 × 10−13 0.24 0.007 0.11 – 0.0037 Williams et al. (4),  
Rusu et al. (13)
HNF1A rs483353044 4.96 (1.75–9.92) 2.39 × 10−9 0.0034 0.000024 0 6 × 10−5 0 Estrada et al. (5)
Insulin-like 
growth factor 2
rs149483638 0.78 (0.73–0.83) 5.61 × 10−14 0.19 0.00008 0.008 3 × 10−5 0.0014 Mercader et al. (16)
 aThe association values in the EA population corresponds to variant rs312457, which is in high linkage disequilibrium with rs77086571 (R2 = 0.93). The association of this variant in 
other populations or the rest of the variants in non-Latino populations are not shown as there was not enough power to provide an accurate estimate of the effect sizes due to the 
low frequency in non-Latino populations.
MAF, minor allele frequency, taken from gnomAD (http://gnomad.broadinstitute.org/), EU, Europeans; EA, East Asian; SA, South Asians; AA, African Americans.
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vivo. Interestingly, higher expression of isoform 2 of IGF2 in 
adipose tissue was associated with T2D and with increased 
plasma glycated hemoglobin (HbA1c) in individuals without 
diabetes in vivo. These results suggest that reducing the levels 
of this isoform could be a therapeutic strategy for preventing 
or treating T2D. The identification of loss-of-function variants 
associated with reduced risk of disease is of particular interest, 
as their protective genetic effect can be potentially recapitulated 
by pharmacological inhibition (which is typically easier to 
achieve than activation). However, to assess the viability of such 
a strategy, it is crucial to exclude the possibility that carriers of 
these T2D-protective variants might be at increased risk for 
other conditions, so as to reduce the chance of potential adverse 
effects when instituting a therapy that targets this mechanism 
(17). To mitigate this concern, we performed a phenome-wide 
association study and showed that individuals lacking this 
isoform did not show increased risk for a number of other com-
mon diseases nor reduced fertility, suggesting that reducing the 
levels of this isoform does not result in major adverse effects on 
health or reproduction. Because loss-of-function of this isoform 
is associated with reduced risk of T2D and shows no evidence 
of increased risk for other diseases, this isoform is proposed 
as a potential therapeutic target for T2D. It should be noted 
that the approach could be extended beyond Latin Americans, 
as isoform 2 of IGF2 is expressed also in non-carriers of the 
rs149483638 variant. In addition, this discovery also opens a 
new unexplored area of research around this minor alterna-
tively spliced isoform of IGF2, as further functional studies are 
needed to elucidate the precise mechanism of action of IGF2 
isoform 2 and its impact on glycemic physiology.
Studies in Other Latin American 
Ancestries
Contemporary Hispanic/Latino individuals may descend from 
diverse ancestries, each of which may be associated differently 
with T2D (18). The genetic complexity of Latino or Hispanic 
individuals often reflects various proportions of admixed 
genomes from three main ancestries, including indigenous 
American, European, and West African. For example, due to 
historical circumstances Puerto Ricans or Dominicans typically 
possess higher proportions of African ancestry, Mexicans or 
Bolivians typically carry higher proportions of Native American 
ancestry, while Chileans or Argentinians on average carry 
higher proportions of European ancestry. Latino admixture 
occurred first between Native American and Europeans around 
11 generations ago, which was followed by African admixture 7 
generations ago (19). On average, Latinos in the US carry 18% 
Native American ancestry, 65% European, and 6.2% African 
Ancestry. In the US, individuals who self report as Hispanic 
and Mexican or Central American tend to have higher Native 
American ancestry than the rest of the Latinos. By contrast, 
those individuals reported as black, Puerto Rican, or Dominican 
have higher ancestries of African ancestry. Finally, those that 
self report as white, Cuban, or South American have higher 
levels of European ancestry (19).
Each of these differences in ancestries, as well as the degree 
of admixture, needs to be carefully taken into account to avoid 
artifactual associations driven by confounders (population 
stratification). Several methods that address the particularities of 
Hispanic and Latino populations have been developed and shown 
to overcome this type of inflation (20).
A recent study reported the GWAS results for the Hispanic 
Health Study/Study of Latinos (HCHS/SOL) (21). The unique-
ness of this study is that it analyzed six different Hispanic ethnic 
groups, which provides the opportunity to identify ancestry-
specific alleles associated with T2D. For example, this allowed 
the identification of an additional African ancestry-specific 
independent allele at KCNQ1, which was further replicated 
in the Meta-analysis of type 2 DIabetes in African Americans 
(MEDIA) consortium (22). The authors of the HCHS/SOL study 
acknowledge that their study was underpowered to detect mod-
est effect sizes at genome-wide significance, but demonstrated 
that the previously reported 80 index variants consistently 
showed the same direction of effect (i. e., the risk allele was the 
same for the majority of the variants). Larger GWAS focusing 
on each of the Hispanic ancestry groups should be pursued in 
order to identify additional ethnic specific variants associated 
with T2D.
Genetic Association with Glycemic Traits
Individuals with T2D display insulin resistance and impair-
ment of beta-cell function and insulin secretion. Testing the 
association between genetic variants and additional glycemic 
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traits can be very useful to understand the mechanism by 
which the associated variants increase T2D risk (23). Studying 
glycemic traits in European populations has provided a large 
number of genetic variants associated with several glycemic 
traits (24–26) and allowed the classification of genetic variants 
that influence the risk for T2D by modulating different mech-
anisms, including insulin secretion and insulin sensitivity. 
More recently, the GUaRDIAN (Genetics Underlying Diabetes 
in Hispanics) Consortium was formed in order to characterize 
the genetic components of insulin sensitivity, insulin secre-
tion, insulin clearance, and glucose effectiveness in 4,176 
Mexican Americans (27). This study revealed a genome-wide 
significant association at MTNR1B (rs10830963) with acute 
insulin response in a locus that was previously reported to 
be associated with fasting glucose levels in Europeans (28). 
Further fine-mapping performed in a total of 27,206 cases 
and 57,574 controls of European ancestry confirmed that 
the association was driven by the rs10830963 variant, which 
was proven to disrupt a transcription factor binding site 
for NEUROD1 in the islet-derived cells EndoC-βH1 (29). A 
limitation of this study is that genotype imputation with 1000 
Genomes reference panel was not performed, which hinders 
the assessment of less common variants and the translation of 
some of the findings described above to examine their effects 
on glycemic traits.
CHALLenGeS AnD LiMiTATiOnS OF 
GeneTiC STUDieS in LATin AMeRiCAnS
While substantial progress has been made in the study of non-
European ancestries, including the Latin American populations, 
several challenges persist that limit discoveries and their follow-
up in non-European ethnic groups.
improved Reference Panels for imputation
One major limitation is the reduced resolution of GWAS analyses 
compared to which can be achieved in European populations. A 
key step in modern GWAS is the imputation of genotypes, for 
which a population-specific reference panel is required (30). 
The ability to impute low-frequency variants is highly depend-
ent on the number of haplotypes that carry each given variant 
in the reference panel. Following this notion, larger reference 
panels have been assembled for the European population, such 
as the Haplotype Reference Consortium (31), representing 
64,976 haplotypes, which enables the high-quality imputation 
of variants with frequencies higher than 0.1%. However, the 
largest source for imputation available for the Latin American 
population is Phase 3 of the 1000 Genomes panel, which contains 
only 694 individuals of Latin American ancestry (32). This places 
the genetic studies performed in non-European populations at 
a disadvantage when there is a need to identify low-frequency 
variants associated with complex diseases. For example, while a 
variant such as HNF1A E508K (MAF~0.36%) could be properly 
imputed if it was present in Europeans, this variant cannot cur-
rently be imputed in Latinos due to the lack of sufficiently large 
Latino-specific samples in current reference panels. To address 
this block, the ongoing NHLBI-funded initiative, the Trans-
Omics for Precision Medicine (TOPMed, https://www.nhlbi.
nih.gov/research/resources/nhlbi-precision-medicine-initiative/
topmed/wgs), will release high coverage whole-genome sequenc-
ing data of 62,000 participants, of whom 10% are of Hispanic 
ancestry. This sequence data will eventually be very valuable as a 
highly precise reference panel for genotype imputation in Latin 
Americans.
Availability of Functional Genomic  
Data for non-europeans
The majority of genetic associations with complex diseases, 
including those in T2D, fall within non-coding regions: only in a 
few cases can a coding variant that drives the association signal 
for a non-coding proxy be identified and presumed to be causal 
to enable the design of functional experiments. Non-coding 
variation is less well characterized for functional impact, which 
makes a mechanistic interpretation challenging. Currently, the 
interrogation of expression quantitative trait loci (eQTLs) is a 
powerful tool to assess if a non-coding variant has a regulatory 
effect, and additionally identify the effector genes and tissue of 
action for a given association. The GTEx Consortium represents 
one of the largest multi-tissue eQTL dataset, as it consists of 
genotype and gene expression data for 544 individuals and 53 tis-
sues (33). However, a very negligible fraction of Latin American 
individuals are represented in this dataset, preventing the analysis 
of population-specific associations. Likewise, large collections of 
pancreatic islets gene expression and genotyping data are available 
for the European population, but practically none of the samples 
are from Latino ancestry (34). Until a similar resource such as 
GTEx begins to cover non-European ancestries, investigators will 
need to collect the tissues from the population where the variant 
was discovered, genotype the samples, measure gene expression 
of the nearby genes, and test them for association with the variant. 
This non-trivial experimental step introduces a substantial delay 
in following up association results, in contrast to a simple lookup 
in the GTEx portal of every variant with a frequency higher than 
1% in European populations.
Therefore, significant investment is needed to assemble the 
first eQTL datasets including Latin American samples, perhaps 
starting with relevant tissues for T2D such as pancreatic islets, in 
order to improve the interpretation of the GWAS results in these 
populations.
Large-Scale Phenotypically Rich Cohorts
Once a genetic association with a disease such as T2D is discov-
ered, it can be very useful to analyze whether this association 
is specific for T2D or it is also associated with other traits or 
diseases. This can be specifically relevant as follow-up of loss-
of-function protective variants for T2D. Before considering an 
association as a potential therapeutic target, phenome-wide 
association analysis can allow discarding the possibility that 
the protective variant might be associated with increased risk 
of other diseases or impair fertility. Large-scale biobanks with 
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genetic data, such as the UK Biobank (35, 36), the Kaiser 
Permanente Research Program on Genes, Environment and 
Health: A Genetic Epidemiology Research on Adult Health and 
Aging (GERA) cohort (37), or the China Kadoorie Biobank (38) 
can facilitate this search. However, such a resource does not exist 
for Latin American populations and prevents carrying out this 
analysis for variants that are Latino-specific.
COnCLUSiOn AnD FUTURe 
PeRSPeCTiveS
The study of genetics of T2D in Latin Americans is still in 
its infancy, but has already provided exciting and promising 
results. The sample size of the largest studies (~9,000 cases and 
controls) currently analyzed in Latin American populations is 
comparable to those published in 2008 for Europeans, but has 
already provided several novel findings of potential therapeutic 
relevance that would also be applicable beyond the population 
where they were discovered. This should serve as a motivation 
to pursue larger-scale association analyses to find additional 
relevant therapeutic targets and to better understand the 
pathophysiology of T2D. While increasing the sample size or 
extending the allele frequency spectrum in European popula-
tions can provide additional novel associations for T2D, the 
expected population impact of the novel associations will be 
smaller, as the associations would have been identified earlier 
otherwise. However, studying different populations may provide 
novel associations with larger effect sizes that might be more 
amenable to functional studies.
In parallel to focusing on increasing the sample sizes of 
GWAS in Latin American populations, genomic resources that 
enable the functional interpretation of genetic results and build-
ing infrastructures to establish large-scale biobanks with access 
to genetic information will enhance the success of the discovery 
of potential therapeutic targets in these populations.
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